Schizophrenia & Psychoses
A comparative dosing and titration chart of commonly used first-generation and second-generation antipsychotics.
A substantial proportion of these individuals diagnosed with HIV, psychiatric disorders, and substance use disorders are out of care and urgently require intervention.
The superior benefit provided by early intervention services for schizophrenia could be cost-effective, and the researchers call for widespread implementation and funding of early intervention services in the United States and globally.
To date, there has been limited prognostic accuracy of clinical instruments in predicting the onset of psychosis and no reliable biological marker has been identified.
These data may be helpful in titrating care for those with schizotypal disorder and comorbid substance abuse disorders to mitigate the risk for conversion to schizophrenia.
These data may be useful to clinicians in considering the risks and benefits of prescribing haloperidol for patients with cardiac morbidity.
The authors pointed to a possible difference in the specific symptoms alleviated by different types of stimulation.
The early sustained recovery group was more likely to have a diagnosis other than schizophrenia, particularly mania or brief psychosis.
Although various clinical and psychosocial factors were associated with unhealthy lifestyle factors and higher risk for CVD, the strongest associations were with negative symptoms.
Treatment beyond antipsychotic drugs is needed for people with schizophrenia, as positive symptoms are a peripheral node in the network.
Given the high risk for metabolic disorder and type 2 diabetes, clinicians should select psychotropic medications carefully and monitor metabolic conditions regularly in their patients with serious mental illness.
The meta-analysis showed raloxifene to be effective for positive symptoms, negative symptoms, and general psychopathology, with greatly homogeneous results.
Investigators selected 15 genes associated with schizophrenia due to high expression in both brain tissue and B-lymphocyte cells.
Use of virtual reality environments in which participants interact with computer-controlled situations or avatars enables a more fine-tuned approach to exposure in the context of cognitive behavioral therapy.
tDCS may be an important tool for further improving our understanding of psychosis and designing targeted treatments.
Researchers examined which atypical antipsychotic was more effective and safe in first-episode drug-naive schizophrenia.
A chart outlining the pharmacokinetics of atypical antipsychotics, including information on bioavailability, half-life and CYP 450 metabolism.
A meta-analysis of randomized, controlled trials compared the use of benzodiazepines alone or in combination with antipsychotic or antihistamine medications in patients experiencing acute psychotic illness.
Investigators seek the association between psychosis and complication risk after total joint arthroplasty.
P50 processing may inform researchers in the future development of interventions targeting cognitive impairment in schizophrenia.
A chart with daily dose thresholds for antipsychotic medications.
Investigators seek the association between the risk of developing schizophrenia and advanced maternal and paternal age.
Gender differences may predict the types of symptoms and age of onset of schizophrenic psychosis.
Investigators assessed biomarkers for cardiovascular risk and protection in individuals with first-episode psychosis.
Investigators believe social recovery therapy may benefit individuals with complex comorbidities not motivated to participate in psychosocial interventions targeting functioning after first-episode psychosis.
Technique validation suggested a robust generalizability of neuroanatomical imaging in schizophrenia.
The ability to track ingestion of medications prescribed for mental illness may be useful for some patients.
Type 2 diabetes is greater with second-generation antipsychotics than with non-second-generation antipsychotic psychotropic medications for patients aged 6 to 25 years.
The FDA issued a refusal to file letter for a new drug application.
Different clinical and neurobiologic pathways may be involved in treatment-resistant schizophrenia as it is not a homogeneous subgroup within the schizophrenia spectrum.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Attention-Deficit/Hyperactivity Disorder Increasing Among US Children and Adolescents
- Combination Cognitive Behavioral Therapy With Fluoxetine Effective for Adolescent Depression
- Improving Medication Adherence in ADHD Lowers Risk for Oppositional Defiant Disorder, Conduct Disorder in Adulthood
- Antidepressant Effects of Ketamine Appear to Require Opioid System Activation
- Prazosin May Be Effective as Treatment for Alcohol Use Disorder
- Aggression in Bipolar I Disorder and Psychosis Associated With Suicide Ideation, Alcohol Abuse
- Moving Associated With Increased Risk for Psychosis in Children, Adolescents
- Omega-3 Polyunsaturated Fatty Acids Associated With Reduction in Anxiety Symptoms
- Neuroimaging Markers of Bipolar Disorder Risk for At-Risk Youth
- Suicide Attempt Risk Among LGB Populations Higher Than Previously Estimated